GSK's Arexvy RSV Vaccine: Three-Year Efficacy and CDC Recommendations Challenges

GSK's Arexvy vaccine represents a significant advancement as the first market entrant for RSV, targeting older adults 60 and above. The vaccine demonstrated a cumulative efficacy of 62.9% against RSV-associated lower respiratory tract disease (LRTD) across three seasons, with an efficacy of 67.4% against severe cases[1][2]. However, effectiveness declined to 48% during the third season, highlighting the potential need for revaccination, though currently, a second dose is not recommended by the CDC[2]. Despite the vaccine's success, the CDC's narrower recommendations, due to potential links to Guillain-Barré syndrome, pose challenges, affecting projected market values[1].